Remarkably, the reduction of G3BP1 levels through YB-1 globally acetylation by MS-275 treatment reduces the sarcoma metastasis and reduces the premetastatic activity of the G3BP1 factor (El-Naggar and Sorensen, 2018). Here, G3BP1 is linked to sarcoma.